Inari Medical, Inc. (NASDAQ: NARI) shares surged 8.06% in pre-market trading on October 29, 2024, following the company's impressive third-quarter financial results and raised full-year revenue guidance.

For the third quarter ended September 30, 2024, Inari Medical reported revenue of $153.4 million, representing a 21.4% increase compared to the same period last year. The strong revenue growth was driven by an expansion in sales territories, opening of new accounts, increased adoption of the company's procedures, global commercial expansion, and the introduction of new products.

Notably, Inari Medical's revenue figure surpassed analysts' expectations, and the company raised its full-year 2024 revenue guidance to a range of $601.5 million to $604.5 million, reflecting an increase of $3.5 million at the midpoint from its prior outlook. The company also expects to achieve sustained operating profitability in the first half of 2025, indicating an improved profitability outlook.